Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APSMNF 2
- Development stage
- Unknown
- Lead developer
- Apsen Farmacêutica
- Administration
- Topical
01
Overview
**APSMNF 2** is an investigational Apsen pharmaceutical treatment arm being evaluated in the Phase 3 MONA trial for male androgenetic alopecia. The publicly available trial record identifies APSMNF 2 as a distinct experimental intervention from APSMNF 1 and the active comparator Eniagor, but does not disclose its active ingredient composition, formulation, route of administration, or mechanism of action. ([ctv.veeva.com](https://ctv.veeva.com/study/efficacy-and-safety-of-apsmnf-in-the-treatment-of-male-androgenetic-alopecia))
Beyond the preview
Go deeper on APSMNF 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APSMNF 2.